Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ramipril 10 mg/Day in Prevention of Cardiovascular Events
NCT01053910Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2003
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ramipril in atherosclerosis, sponsored by Sanofi. Primary endpoints: Number of patient reaching the 10mg/day dose level at 30 days and Overall number of adverse events at Day 60. Started Oct 2003; status: completed.
02
Drugs
ramipril
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT01053910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01053910.